Quarterly report · Q2
4548.TEDINET S100SALX
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥79.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥77.8bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥71.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥69.8bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.0bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥490m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥268m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥731m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.54 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.93 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥29.72 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥420m |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥18.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.6bn |
| jpcrp040300-q2r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥17.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 525
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 7843000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1438 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 7458000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1367 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 7293000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.1337 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1573000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0288 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1536000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0282 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 1369000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0251 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1277000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0234 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1207000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0221 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 828000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0152 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 688000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0126 | |
| Number of shares held | CurrentQuarterInstant | 31074000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5695 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2253600 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 54509600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 545096 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 50893 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 56814093 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 545096 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 2253600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 2253600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0397 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 2253600 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 2253600 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0397 | |
| Cash and deposits | Prior1YearInstant | 23451000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 18042000000 | JPY |
| Notes receivable trade | Prior1YearInstant | 59000000 | JPY |
| Notes receivable trade | CurrentQuarterInstant | 89000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 6349000000 | JPY |
| Accounts receivable trade | CurrentQuarterInstant | 8471000000 | JPY |
| Short term investment securities | Prior1YearInstant | 5327000000 | JPY |
| Short term investment securities | CurrentQuarterInstant | 5346000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 3469000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 3158000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |